InsidersTradesSigma
Track the Mannkind CORP share price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Mannkind CORP has published 194 insider filings. Market capitalisation: €1.3bn. The latest transaction was disclosed on 10 August 2026 (Cession). Among the most active insiders: Castagna Michael. All data is openly available.
194
Insider Decl.
n/a
Thresholds
€732,330
21 ops.
Buy Volume
€2m
20 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Mannkind CORP Strong Buy (bullish), based on 8 analysts. Average price target: US$7.97.
47Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,920 of 29,063 companies
36.9
score / 100
Value30
Quality44
FCF yld1.1%
Earn yld0.5%
EV/EBITDA32.2x
ROE·
Gross mgn75%
Net mgn1.7%
Debt/EBITDA7.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 10 August 2026
Declarations194 total
39,051 shares@ US$4.06Common Stock, $0.01 Par ValueSEC:0001193125-26-343016:0
93,790 shares0Common Stock, $0.01 Par ValueSEC:0001193125-26-308129:0
350,260 shares0Common Stock, $0.01 Par ValueSEC:0001193125-26-308133:0
47,481 shares@ US$4.090.016% mcap2.0% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308133:2
63,996 shares@ US$4.090.022% mcap2.7% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308133:3
93,790 shares0Common Stock, $0.01 Par ValueSEC:0001193125-26-308134:0
4,634 shares@ US$4.090.0016% mcap0.4% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308129:3
52,485 shares@ US$4.060.018% mcap4.3% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308129:4
12,662 shares@ US$4.090.0043% mcap1.5% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308131:2
15,688 shares@ US$4.090.0054% mcap1.3% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308129:1
4,073 shares@ US$4.090.0014% mcap0.3% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308129:2
192,819 shares@ US$4.090.066% mcap8.0% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308133:1
58,904 shares@ US$4.090.020% mcap2.5% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308133:4
93,790 shares0Common Stock, $0.01 Par ValueSEC:0001193125-26-308131:0
51,632 shares@ US$4.090.018% mcap6.1% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308131:1
17,754 shares@ US$4.090.0061% mcap2.1% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308131:3
16,378 shares@ US$4.090.0056% mcap1.9% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308131:4
24,109 shares@ US$4.050.0081% mcap2.8% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308131:5
70,550 shares0Common Stock, $0.01 Par ValueSEC:0001193125-26-308132:0
22,047 shares@ US$4.090.0075% mcap22.1% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308132:1
5,372 shares@ US$4.090.0018% mcap5.4% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308132:2
10,079 shares@ US$4.090.0034% mcap10.1% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308132:3
9,297 shares@ US$4.090.0032% mcap9.3% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308132:4
33,652 shares@ US$4.090.011% mcap3.3% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308134:1
8,253 shares@ US$4.090.0028% mcap0.8% of flowCommon Stock, $0.01 Par ValueSEC:0001193125-26-308134:2
25 of 194 declarations
关于 Mannkind CORP
MannKind Corp.（股票代码MNKD）是一家在美国纳斯达克上市的美国生物制药公司。公司成立于1991年，目前总部位于康涅狄格州丹伯里，专注于开发和商业化针对严重慢性疾病的创新治疗产品和给药装置。其核心战略围绕心血管代谢和罕见肺部疾病，制造和技术运营均设在康涅狄格州。([investors.mannkindcorp.com](https://investors.mannkindcorp.com/investor-relations?utm_source=openai)) 该公司最著名的资产是Afrezza®，一种超速效吸入式人胰岛素，用于改善成人糖尿病患者的血糖控制。MannKind还拥有Technosphere®平台，这是一种专有的吸入技术，支撑着多款产品和合作项目。该平台已用于Tyvaso DPI®，这是United Therapeutics公司商业化用于肺动脉高压和与间质性肺病相关的肺动脉高压的产品。这使得MannKind拥有直接产品销售和特许权使用费收入的组合，使其业务模式比单一产品生物技术公司更加多元化。([mannkindcorp.com](https://mannkindcorp.com/about/?utm_source=openai)) 在2025年末至2026年，MannKind的商业版图通过新增FUROSCIX和V-Go®进一步扩大，FUROSCIX是一种已上市的呋塞米疗法，用于治疗心力衰竭或肾脏疾病相关的液体超负荷，V-Go®则是一种胰岛素输送装置。管理层还强调了近期监管催化剂，包括FDA正在审查的Afrezza儿科申请，以及MNKD-201（尼达尼布DPI）等管线项目和其他吸入式资产。2026年5月，公司宣布与United Therapeutics合作开发ralinepag DPI项目，这进一步强化了战略伙伴关系在MannKind增长中的重要性。([investors.mannkindcorp.com](https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-acquire-scpharmaceuticals-accelerating-revenue-growth?utm_source=openai)) 从竞争角度看，MannKind是一个专业的利基市场参与者，而非大型制药巨头。其优势在于吸入科学、差异化的药物-器械组合，以及在便利性、依从性和患者体验至关重要的领域中，将合作资产变现的能力。对于投资者而言，MNKD最好被视为一家处于商业化阶段的生物制药公司，拥有多个运营杠杆，但仍面临FDA审批时间风险、执行风险和一定的收入集中度风险。最近的业务更新表明，该公司正努力拓宽其商业资产基础，同时通过管线开发和外部合作保持选择性。([investors.mannkindcorp.com](https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-provides-business-updates-and-2026-growth-drivers?utm_source=openai))
